Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
DOCA-PHARMA from Sint-Niklaas, company number BE1013386219, closed financial year 2025 with a result of € -64,546 after tax. For that financial year DOCA-PHARMA recorded a gross margin of € -27,380 and equity of € -79,753. Compared with financial year 2024, the result moved from € -20,208 to € -64,546. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ -79,753
▼ € 64,546 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -64,546
▼ 219 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1,237
▼ 97% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -84,753.
People and assets in 2025
€ 24,104
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 35,301
▼ 18% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 140,000
▲ 40% vs 2024
€ 50,000 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1,696
▲ 109% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 4,696
▲ € 4,111 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -18,752 | € -27,380 | ▼ € 8,628 |
| Profit after taxes | € -20,208 | € -64,546 | ▼ € 44,338 |
| Equity | € -15,208 | € -79,753 | ▼ € 64,546 |
| Total debts | € 104,490 | € 152,137 | ▲ 46% |
| Cash | € 38,344 | € 1,237 | ▼ 97% |
| Retained profit | € -20,208 | € -84,753 | ▼ € 64,546 |
| Bank debt | € 100,000 | € 140,000 | ▲ 40% |
| Balance sheet total | € 89,282 | € 72,384 | ▼ 19% |
Key figures of DOCA-PHARMA, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DOCA-PHARMA?
What happened at DOCA-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 64,546. Source: NBB ↗
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 20,208 loss in 2024 to € 64,546 loss in 2025.
A new publication or filing at DOCA-PHARMA? We notify you, reason included.
Follow DOCA-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DOCA-PHARMA are Casper De Pryck and Domien Van Acker. Domien Van Acker is also behind DIERENARTS D.H.M. VAN ACKER.
Directors
According to the 2025 annual accounts
Casper De Pryck
Director
Establishments
Establishment units
Physical locations of this company
Edgar Tinelstraat 11
9112 Sint-Niklaas
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
HETZNER-AS, DE
Website info
Features
Security
Details
- Company number
- 1013.386.219
- VAT number
- BE 1013.386.219
- Registered office
- Edgar Tinelstraat 11, 9112 Sint-Niklaas
- Names & denominations
- DOCA-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 September 2024
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- doca-pharma.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Veterinaire diensten
Overige posterijen en koeriers
Overige zakelijke dienstverlening, neg